癌症临床试验中静脉注射维生素C的系统评价。
Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials.
作者信息
Nauman Gina, Gray Javaughn Corey, Parkinson Rose, Levine Mark, Paller Channing J
机构信息
National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Clinical Nutrition Section, Bethesda, MD 20892, USA.
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA.
出版信息
Antioxidants (Basel). 2018 Jul 12;7(7):89. doi: 10.3390/antiox7070089.
BACKGROUND
Ascorbate (vitamin C) has been evaluated as a potential treatment for cancer as an independent agent and in combination with standard chemotherapies. This review assesses the evidence for safety and clinical effectiveness of intravenous (IV) ascorbate in treating various types of cancer.
METHODS
Single arm and randomized Phase I/II trials were included in this review. The PubMed, MEDLINE, and Cochrane databases were searched. Results were screened by three of the authors (GN, RP, and CJP) to determine if they met inclusion criteria, and then summarized using a narrative approach.
RESULTS
A total of 23 trials involving 385 patients met the inclusion criteria. Only one trial, in ovarian cancer, randomized patients to receive vitamin C or standard of care (chemotherapy). That trial reported an 8.75 month increase in progression-free survival (PFS) and an improved trend in overall survival (OS) in the vitamin C treated arm.
CONCLUSION
Overall, vitamin C has been shown to be safe in nearly all patient populations, alone and in combination with chemotherapies. The promising results support the need for randomized placebo-controlled trials such as the ongoing placebo-controlled trials of vitamin C and chemotherapy in prostate cancer.
背景
抗坏血酸（维生素C）已被评估为一种潜在的癌症治疗方法，可单独使用或与标准化疗联合使用。本综述评估了静脉注射抗坏血酸治疗各种类型癌症的安全性和临床有效性证据。
方法
本综述纳入了单臂和随机I/II期试验。检索了PubMed、MEDLINE和Cochrane数据库。结果由三位作者（GN、RP和CJP）进行筛选，以确定是否符合纳入标准，然后采用叙述性方法进行总结。
结果
共有23项涉及385名患者的试验符合纳入标准。只有一项卵巢癌试验将患者随机分为接受维生素C或标准治疗（化疗）组。该试验报告，接受维生素C治疗的组无进展生存期（PFS）延长了8.75个月，总生存期（OS）有改善趋势。
结论
总体而言，几乎在所有患者群体中，维生素C单独使用或与化疗联合使用均已证明是安全的。这些有前景的结果支持开展随机安慰剂对照试验的必要性，例如正在进行的维生素C与化疗治疗前列腺癌的安慰剂对照试验。
Zotero 插件